1,721,054 research outputs found
Response to "Why Are Bicuspid Aortic Valve Patients Flying Under the Radar?"
No full textEuropean Society of Cardiology (ESC) [App000064741
Analysis of tricuspid regurgitation improvement following cardiac resynchronization therapy-Authors' reply
No full textDiscussion forum: it is time to assess left ventricular segmental remodelling in aortic stenosis
No full textCardiolog
Impact of latest 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: retrospective single center cohort study
No full textImpact of latest 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: retrospective single center cohort study
No full textOptimization of guideline-directed medical treatment to reduce secondary mitral regurgitation: treat the ventricle, not only the valve
No full textCardiolog
Comparison of de novo versus upgrade cardiac resynchronisation therapy on clinical effect and long-term outcome
No full textBackground: The benefit of de novo cardiac resynchronisation therapy (CRT) implantation in selected patients with heart failure is well known. The number of upgrade procedures is increasing but data on clinical response and outcome are less well documented as compared to de novo implantation. Objectives: To investigate the efficacy and outcome of CRT upgrade procedures in patients with existing cardiac implantable electronic devices (CIEDs). Methods: Baseline characteristics, change in New York Heart Association (NYHA) functional class, echocardiographic parameters, life-threatening ventricular tachyarrhythmias, all-cause mortality and mode of death were evaluated in CRT patients with the comparison between de novo and upgrade CRT procedures. Results: About 410 patients (CRT upgrade/de novo CRT, n = 97/313) were followed for 63.5 +/- 38.1 months. Upgrade patients were older (75.5 +/- 8.1 vs 69.9 +/- 10.7 years; p < 0.001), had more often an ischaemic cause of heart failure (58.8% vs 45.4%; p = 0.021), a higher NYHA functional class (p = 0.004) and a higher comorbidity burden. Improvement in left ventricular ejection fraction (LVEF) was higher in the de novo CRT group (8.4 +/- 9.9 vs 11.0 +/- 10.3%; p = 0.035). Clinical response was similar between both groups (60.5 vs 62.5%; p = 0.793), as was mortality at 1 year (8.2 vs 5.8%; p = 0.351) and at last follow-up (33.0 vs 28.8%; p = 0.447). The proportion of cardiovascular related deaths was similar between both groups (46.9% vs 38.9%; p = 0.531). Conclusions: Patients with CRT upgrade procedures have similar symptomatic improvements, as well as 1 year and long-term outcome as compared to patients with de novo CRT implantation.Stassen, J (corresponding author), Jessa Hosp Hasselt, Stadsomvaart 11, B-3500 Hasselt, Belgium.
[email protected]
Using a deep learning algorithm to score coronary artery calcium in myocardial perfusion imaging: A real opportunity or just a new hype?
Full text linkCardiolog
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
- …
